Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib Plus Toripalimab in Frail Patients with Advanced Gastric Cancer
NCT04278222Phase 2Recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Feb 2020
- Primary completion
- Oct 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib and toripalimab in gastric cancer (GC), sponsored by Shanghai Changzheng Hospital. Primary endpoint: Objective Response Rate at 8 weeks. Started Feb 2020; status: recruiting.
02
Drugs
anlotinibtoripalimab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT04278222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04278222.